Genprex, Inc. (GNPX)
- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $2.51
- As of
Kresmion compiles this page from GNPX's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
Genprex, Inc. (GNPX): no institutional manager tracked by Kresmion reported a non-option position in the latest Form 13F reporting quarter, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-08-18.
See the full GNPX dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for GNPX on one page. Preview it with sample data, then open it live with a free account.
Preview the GNPX dossierActive signals for GNPX
- mediumEARNINGS_BEAT
Q3-2024: Beat consensus by 37.5% - EPS $-61.5 vs $-98.43 estimate
- mediumEARNINGS_MISS
Q4-2024: Missed consensus by 189.1% - EPS $-57.5 vs $-19.89 estimate
- mediumEARNINGS_BEAT
Q1-2025: Beat consensus by 37.8% - EPS $-13 vs $-20.91 estimate
- mediumEARNINGS_BEAT
Beat consensus by 37.5% - EPS $-61.5 vs $-98.43 estimate
- mediumEARNINGS_MISS
Missed consensus by 189.1% - EPS $-57.5 vs $-19.89 estimate
FREE, NO ACCOUNT
Every signal on GNPX, as it fires
You are seeing 5 of 6 signals recorded on GNPX since 2026-05-31.
The five above landed across 2 days. The other 1 were recorded on those same days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
No non-option holdings from tracked managers in this reporting quarter. Historical quarters remain available above.
Recent SEC filings, GNPX
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
GNPX against its peers
GNPX's return on equity of -203.8% ranks in the 41st percentile of 10 Biotechnology sub-industry peers, fiscal periods ending between 2025-12-31 and 2026-03-31.
| Metric | GNPX | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | n/a | 721000 | n/a | 10 |
| Operating margin | n/a | -869.3% | n/a | 9 |
| Net margin | n/a | -862.3% | n/a | 9 |
| Return on equity | -203.8% | -166.4% | 41 | 10 |
| 1 year | n/a | -93.8% | n/a | 13 |
Peers (18): ISCO, OGEN, BCAB, CASIF, TCRT, VSBC, VBIO, ABPO, PPBT, ACUT, CRIS, ARTL, GOVX, SILO, VIVS, MTNB, ADTX, SCNI. Left out: GPLL (period gap), ELAB (no annual filing), LABT (no annual filing), BIXT (no annual filing), VRAX (period gap), LSBCF (period gap), VCNX (period gap). Fiscal periods ending between 2025-12-31 and 2026-03-31. Every figure is one full fiscal year read from one annual filing (GNPX: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow GNPX on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to GNPX for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.